Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk

Mary Beth Terry; Mary Daly; Kelly Anne Phillips; Xinran Ma; Nur Zeinomar; Nicole Leoce; Gillian S. Dite; Robert J. MacInnis; Wendy K. Chung; Julia A. Knight; Melissa C. Southey; Roger L. Milne; David E. Goldgar; Graham G. Giles; Prue C. Weideman; Gord Glendon; Richard Buchsbaum; Irene L. Andrulis; Esther M. John; Saundra S. Buys; John L. Hopper

doi:10.1093/jnci/djy182

Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk

Mary Beth Terry, Mary Daly, Kelly Anne Phillips, Xinran Ma, Nur Zeinomar, Nicole Leoce, Gillian S. Dite, Robert J. MacInnis, Wendy K. Chung, Julia A. Knight, Melissa C. Southey, Roger L. Milne, David E. Goldgar, Graham G. Giles, Prue C. Weideman, Gord Glendon, Richard Buchsbaum, Irene L. Andrulis, Esther M. John, Saundra S. BuysJohn L. Hopper

Research output: Contribution to journal › Article › peer-review

32 Scopus citations

Abstract

There remains debate about whether risk-reducing salpingo-oophorectomy (RRSO), which reduces ovarian cancer risk, also reduces breast cancer risk. We examined the association between RRSO and breast cancer risk using a prospective cohort of 17917 women unaffected with breast cancer at baseline (7.2% known carriers of BRCA1 or BRCA2 mutations). During a median follow-up of 10.7 years, 1046 women were diagnosed with incident breast cancer. Modeling RRSO as a time-varying exposure, there was no association with breast cancer risk overall (hazard ratio [HR] = 1.04, 95% confidence interval [CI]=0.87 to 1.24) or by tertiles of predicted absolute risk based on family history (HR=0.68, 95% CI=0.32 to 1.47, HR=0.94, 95% CI=0.70 to 1.26, and HR=1.10, 95% CI=0.88 to 1.39, for lowest, middle, and highest tertile of risk, respectively) or for BRCA1 and BRCA2 mutation carriers when examined separately. There was also no association after accounting for hormone therapy use after RRSO. These findings suggest that RRSO should not be considered efficacious for reducing breast cancer risk.

Original language	English
Pages (from-to)	331-334
Number of pages	4
Journal	Journal of the National Cancer Institute
Volume	111
Issue number	3
DOIs	https://doi.org/10.1093/jnci/djy182
State	Published - Mar 1 2019

Keywords

Adult
BRCA1 Protein/genetics
BRCA2 Protein/genetics
Breast Neoplasms/etiology
Female
Follow-Up Studies
Genetic Predisposition to Disease
Humans
Middle Aged
Mutation
Ovarian Neoplasms/genetics
Ovariectomy/methods
Prognosis
Prospective Studies
Risk Reduction Behavior

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/jnci/djy182

Cite this

Terry, M. B., Daly, M., Phillips, K. A., Ma, X., Zeinomar, N., Leoce, N., Dite, G. S., MacInnis, R. J., Chung, W. K., Knight, J. A., Southey, M. C., Milne, R. L., Goldgar, D. E., Giles, G. G., Weideman, P. C., Glendon, G., Buchsbaum, R., Andrulis, I. L., John, E. M., ... Hopper, J. L. (2019). Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk. Journal of the National Cancer Institute, 111(3), 331-334. https://doi.org/10.1093/jnci/djy182

@article{15417e1c1fa14a0cb6f744c71e979ab4,

title = "Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk",

abstract = "There remains debate about whether risk-reducing salpingo-oophorectomy (RRSO), which reduces ovarian cancer risk, also reduces breast cancer risk. We examined the association between RRSO and breast cancer risk using a prospective cohort of 17917 women unaffected with breast cancer at baseline (7.2% known carriers of BRCA1 or BRCA2 mutations). During a median follow-up of 10.7 years, 1046 women were diagnosed with incident breast cancer. Modeling RRSO as a time-varying exposure, there was no association with breast cancer risk overall (hazard ratio [HR] = 1.04, 95% confidence interval [CI]=0.87 to 1.24) or by tertiles of predicted absolute risk based on family history (HR=0.68, 95% CI=0.32 to 1.47, HR=0.94, 95% CI=0.70 to 1.26, and HR=1.10, 95% CI=0.88 to 1.39, for lowest, middle, and highest tertile of risk, respectively) or for BRCA1 and BRCA2 mutation carriers when examined separately. There was also no association after accounting for hormone therapy use after RRSO. These findings suggest that RRSO should not be considered efficacious for reducing breast cancer risk.",

keywords = "Adult, BRCA1 Protein/genetics, BRCA2 Protein/genetics, Breast Neoplasms/etiology, Female, Follow-Up Studies, Genetic Predisposition to Disease, Humans, Middle Aged, Mutation, Ovarian Neoplasms/genetics, Ovariectomy/methods, Prognosis, Prospective Studies, Risk Reduction Behavior",

author = "Terry, {Mary Beth} and Mary Daly and Phillips, {Kelly Anne} and Xinran Ma and Nur Zeinomar and Nicole Leoce and Dite, {Gillian S.} and MacInnis, {Robert J.} and Chung, {Wendy K.} and Knight, {Julia A.} and Southey, {Melissa C.} and Milne, {Roger L.} and Goldgar, {David E.} and Giles, {Graham G.} and Weideman, {Prue C.} and Gord Glendon and Richard Buchsbaum and Andrulis, {Irene L.} and John, {Esther M.} and Buys, {Saundra S.} and Hopper, {John L.}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2018.",

year = "2019",

month = mar,

day = "1",

doi = "10.1093/jnci/djy182",

language = "English",

volume = "111",

pages = "331--334",

journal = "Journal of the National Cancer Institute",

issn = "0027-8874",

publisher = "Oxford University Press",

number = "3",

}

Terry, MB, Daly, M, Phillips, KA, Ma, X, Zeinomar, N, Leoce, N, Dite, GS, MacInnis, RJ, Chung, WK, Knight, JA, Southey, MC, Milne, RL, Goldgar, DE, Giles, GG, Weideman, PC, Glendon, G, Buchsbaum, R, Andrulis, IL, John, EM, Buys, SS & Hopper, JL 2019, 'Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk', Journal of the National Cancer Institute, vol. 111, no. 3, pp. 331-334. https://doi.org/10.1093/jnci/djy182

TY - JOUR

T1 - Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk

AU - Terry, Mary Beth

AU - Daly, Mary

AU - Phillips, Kelly Anne

AU - Ma, Xinran

AU - Zeinomar, Nur

AU - Leoce, Nicole

AU - Dite, Gillian S.

AU - MacInnis, Robert J.

AU - Chung, Wendy K.

AU - Knight, Julia A.

AU - Southey, Melissa C.

AU - Milne, Roger L.

AU - Goldgar, David E.

AU - Giles, Graham G.

AU - Weideman, Prue C.

AU - Glendon, Gord

AU - Buchsbaum, Richard

AU - Andrulis, Irene L.

AU - John, Esther M.

AU - Buys, Saundra S.

AU - Hopper, John L.

N1 - Publisher Copyright: © The Author(s) 2018.

PY - 2019/3/1

Y1 - 2019/3/1

N2 - There remains debate about whether risk-reducing salpingo-oophorectomy (RRSO), which reduces ovarian cancer risk, also reduces breast cancer risk. We examined the association between RRSO and breast cancer risk using a prospective cohort of 17917 women unaffected with breast cancer at baseline (7.2% known carriers of BRCA1 or BRCA2 mutations). During a median follow-up of 10.7 years, 1046 women were diagnosed with incident breast cancer. Modeling RRSO as a time-varying exposure, there was no association with breast cancer risk overall (hazard ratio [HR] = 1.04, 95% confidence interval [CI]=0.87 to 1.24) or by tertiles of predicted absolute risk based on family history (HR=0.68, 95% CI=0.32 to 1.47, HR=0.94, 95% CI=0.70 to 1.26, and HR=1.10, 95% CI=0.88 to 1.39, for lowest, middle, and highest tertile of risk, respectively) or for BRCA1 and BRCA2 mutation carriers when examined separately. There was also no association after accounting for hormone therapy use after RRSO. These findings suggest that RRSO should not be considered efficacious for reducing breast cancer risk.

AB - There remains debate about whether risk-reducing salpingo-oophorectomy (RRSO), which reduces ovarian cancer risk, also reduces breast cancer risk. We examined the association between RRSO and breast cancer risk using a prospective cohort of 17917 women unaffected with breast cancer at baseline (7.2% known carriers of BRCA1 or BRCA2 mutations). During a median follow-up of 10.7 years, 1046 women were diagnosed with incident breast cancer. Modeling RRSO as a time-varying exposure, there was no association with breast cancer risk overall (hazard ratio [HR] = 1.04, 95% confidence interval [CI]=0.87 to 1.24) or by tertiles of predicted absolute risk based on family history (HR=0.68, 95% CI=0.32 to 1.47, HR=0.94, 95% CI=0.70 to 1.26, and HR=1.10, 95% CI=0.88 to 1.39, for lowest, middle, and highest tertile of risk, respectively) or for BRCA1 and BRCA2 mutation carriers when examined separately. There was also no association after accounting for hormone therapy use after RRSO. These findings suggest that RRSO should not be considered efficacious for reducing breast cancer risk.

KW - Adult

KW - BRCA1 Protein/genetics

KW - BRCA2 Protein/genetics

KW - Breast Neoplasms/etiology

KW - Female

KW - Follow-Up Studies

KW - Genetic Predisposition to Disease

KW - Humans

KW - Middle Aged

KW - Mutation

KW - Ovarian Neoplasms/genetics

KW - Ovariectomy/methods

KW - Prognosis

KW - Prospective Studies

KW - Risk Reduction Behavior

UR - http://www.scopus.com/inward/record.url?scp=85062876660&partnerID=8YFLogxK

U2 - 10.1093/jnci/djy182

DO - 10.1093/jnci/djy182

M3 - Article

C2 - 30496449

SN - 0027-8874

VL - 111

SP - 331

EP - 334

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

IS - 3

ER -

Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Population Studies Facility

Cite this

Risk-reducing oophorectomy and breast cancer risk across the spectrum of familial risk

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Equipment

Population Studies Facility

Cite this